Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
 
  • Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round

    April 10th, 2012 No comments

    Lead investor Banexi Ventures Partners joins strong investment consortium

    Lausanne, Switzerland, April 10, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million.

    Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in the round. Existing institutional investors are BioMedInvest AG, BB BIOTECH VENTURES III, L.P. and Initiative Capital Romandie.

    The proceeds will be used to advance Aleva’s leading-edge neurostimulation products through clinical development up to CE marking. Aleva´s products are based on its proprietary, next-generation microDBS™ technology for Deep Brain Stimulation therapy (DBS).

    DBS is targeting a rapidly growing patient population with Parkinson’s disease, essential tremor and dystonia, which currently consists of over six million people worldwide. Other potential application areas include Alzheimer´s disease and dementia.

    Aleva’s microDBS™ technology has been designed as a next-generation treatment for target-specific brain stimulation, which is supposed to significantly reduce side effects, potential complications and costs associated with DBS therapy.

    “Aleva has built a very attractive investment case by targeting a huge and fast growing market and by chosing a very intelligent approach to ensure fast market penetration,” said Sophie Pierrin-Lepinard, General Partner Healthcare at Banexi Ventures Partners. “In addition, we were impressed by Aleva´s strong, focused management and its very versatile, proprietary technology.”

    “We are very pleased to have closed a Series B financing round only a few months after our initial financing and to have established a strong consortium of leading private equity investors in the healthcare field,” added Jean-Pierre Rosat, CEO of Aleva Neurotherapeutics. “We are looking forward to accelerating the development of our pipeline and to obtaining CE marking for our products. The recent addition of two renowned industry experts to our Board of Directors and the considerable interest of potential partners confirm that our next-generation neurostimulation products address a significant demand on the DBS market.”

    About Aleva Neurotherapeutics:

    Aleva Neurotherapeutics develops next-generation neurostimulation technologies and devices for Deep Brain Stimulation (DBS) therapy. Its solutions are designed to be more versatile, more precise and more efficient than currently available DBS approaches while causing fewer side effects and complications. Based on its proprietary microDBS™ technology, Aleva develops three novel, brain stimulating products with different properties. The first, called directSTIM™, is an intelligent electrode compatible with existing DBS systems; the second, called spiderSTIM™, is a full solution for both intra-surgical and long-term therapeutic use; and the third named cortiSTIM™ is a device for cortical stimulation. All of Aleva’s products are fully compatible with existing DBS technologies and devices.

    The company is a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) Microsystems Laboratory of Prof. Philippe Renaud. Aleva Neurotherapeutics has raised EUR 12.8 million from renowned private and institutional investors, among them BioMedInvest AG, BB Biotech Ventures LP, Banexi Ventures Parters, Initiative Capital Romandie and selected private investors.

    About Banexi Ventures Partners:
    Banexi Ventures Partners is a French independent managing company. Banexi Ventures Partners invests through Venture Capital Funds, in early stage companies with high growth potential and high technology in 3 different sectors: Internet, Electronic and Medical Technologies.
    Banexi Ventures Partners has been operating as BVP team Capital for 14 years and has invested EUR 357 million in 254 companies since 1983. Banexi Ventures Partners has paneuropean investors and some business angels who contribute with their expertise in their specific knowledge area.

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 267,066 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


 

By using this website you agree with our cookie policy